Back

VIVIMED LABS LTD

BEGAMPET

Product Categories

Formulations
ALLOPURINOL (100 MG),BRINZOLAMIDE (1 %) + BRIMONIDINE (0.2 %),CETIRIZINE (10 MG),CIPROFLOXACIN (0.3 %),CIPROFLOXACIN (0.3%) + DEXAMETHASONE (0.05%),DOXYCYCLINE (100 MG),ESCITALOPRAM (10 MG),ETORICOXIB (90 MG),FLUTICASONE (50 MCG),FLUTICASONE (50 MCG) + AZELASTINE (137 MCG),MOMETASONE (50 MCG),NAPROXEN (550 MG),OLOPATADINE (0.2%),RIVAROXABAN (20 MG),TIMOLOL (0.5%)+ BRIMONIDINE (0.2%),TIMOLOL (0.5%)+ BRINZOLAMIDE (1%),ZOLMITRIPTAN (5 MG)

Company Profile

VIVIMED LABS GROUP, HEADQUARTERED IN HYDERABAD, INDIA, IS A LEADING PHARMACEUTICAL COMPANY WITH A STRONG GLOBAL PRESENCE IN FINISHED DOSAGE FORMS. THE GROUP OPERATES WORLD-CLASS MANUFACTURING FACILITIES ACCREDITED BY HEALTH CANADA, PIC/S, AND EAEU, ENABLING SUPPLIES TO 70+ COUNTRIES. FINOSO PHARMA PVT. LTD., THE DEDICATED CDMO ARM OF VIVIMED, OFFERS END-TO-END SOLUTIONS ACROSS THE PHARMACEUTICAL VALUE CHAIN – FORMULATION DEVELOPMENT, DOSSIER PREPARATION, TECHNOLOGY TRANSFER, AND COMMERCIAL MANUFACTURING. WITH A ROBUST IN-HOUSE PORTFOLIO OF 150+ MOLECULES FOR REGULATED AND EMERGING MARKETS, FINOSO SPECIALIZES IN ORAL SOLIDS, LIQUIDS, OPHTHALMICS, AND NASAL SPRAYS. BACKED BY CGMP-COMPLIANT FACILITIES AND A PROVEN TRACK RECORD WITH GLOBAL PARTNERS, THE GROUP IS COMMITTED TO DELIVERING HIGH-QUALITY, COST-EFFECTIVE, AND REGULATORY-COMPLIANT PRODUCTS THAT MEET DIVERSE MARKET NEEDS ACROSS NORTH AMERICA, EUROPE, SEA, LATAM, AFRICA, AND CIS.